Triplet Therapeutics

Triplet Therapeutics raised $59 million to develop gene-silencing treatments for repeat expansion disorders like Huntington's disease, conditions caused by abnormal DNA repetitions that progressively damage the nervous system. Patients with Huntington's experienced devastating cognitive decline and motor dysfunction with no disease-modifying treatments available. The problem was measurable through genetic testing and clinical symptom progression, yet existing alternatives remained limited to symptom management rather than addressing root causes. Despite securing $49 million in Series A funding from Pfizer and others, Triplet ultimately wound down operations. Warning signs included the company's apparent inability to advance development candidates as planned, suggesting preclinical or early clinical challenges with its gene-silencing approach. The gap between ambitious funding and actual progress indicated potential technical hurdles in targeting repeat expansions effectively. Additionally, the involvement of a major pharmaceutical partner like Pfizer in the shutdown suggested internal assessments revealed insurmountable scientific or commercial obstacles that even substantial capital couldn't overcome.